Quinolines and their therapeutic use

1. A compound of formula (I) or a pharmaceutically acceptable salt thereof:

wherein:

R 1 is halogen or cyano;

R 2 is hydrogen or methyl;

R 3 and R 4 are independently —OR 6 , C 1 -C 6 alkyl or C 3 -C 6 cycloalkyl, the latter two groups being optionally substituted by one or more halogen atoms;

R 5 is hydrogen or halogen;

R 6 is C 1 -C 6 alkyl or C 3 -C 6 cycloalkyl, either of which being optionally substituted by one or more halogen atoms;

X is —CH 2 —, —S—, or —O—;

one of Y and Y 1 is hydrogen and the other is OR 6 ; —C(═O)R 7 ;NR 8 SO 2 R 6 or a heterocyclic group selected from furan; thiophene; pyrrole; oxazole; thiazole; imidazole; pyrazole; isoxazole; isothiazole; 1,2,3-oxadiazole; 1,2,4-oxadiazole; 1,3,4-oxadiazole; furazan; 1,2,3-triazole; 1,2,4-triazole; 1,2,3-thiadiazole; 1,2,5-thiadiazole; 1,3,4-thiadiazole; tetrazole; pyridine; pyridazine; pyrimidine; pyrazine; 1,2,4-triazine; and 1,3,5-triazine,

any of which may be optionally substituted by one or more substituents selected from halogen; cyano; C 1 -C 6 alkyl optionally substituted by one or more halogen atoms; C 3 -C 6 cycloalkyl optionally substituted by one or more halogen atoms; hydroxy; C 1 -C 6 alkoxy optionally substituted by one or more halogen atoms; C 1 -C 6 alkyl-O—CH 2 —; C 1 -C 6 alkyl-O—CH(R X )— and C 1 -C 6 alkyl-O—C(R X R Y )— in which the C 1 -C 6 alkyl part is optionally substituted by one or more halogen atoms; NH 2 C(═O)—; R X NHC(═O)—; R X R Y NC

(═O)—; R X R Y NS(═O) 2 —; R X NHS(═O) 2 —; NH 2 S(═O) 2 —; NH 2 —; R X NH—; R X R Y N—; R X S(═O) 2 —; R X C(═O)—; R X S(═O) 2 NH—; R X S(═O) 2 NR Y —; R X C(═O)NH— and R X C(═O)N(R Y )—; wherein R X and R Y are independently C 1 -C 4 alkyl or C 3 -C 6 cycloalkyl, either of which being optionally substituted by one or more halogen atoms; or R X and R Y when attached to the same nitrogen atom form a cyclic amino ring;

R 7 is C 1 -C 6 alkyl or C 3 -C 6 cycloalkyl either of which being optionally substituted by one or more halogen atoms; or phenyl or monocyclic heteroaryl having 5 or 6 ring atoms, optionally substituted by one or more substituents independently selected from halogen; cyano; C 1 -C 6 alkyl optionally substituted by one or more halogen atoms; C 3 -C 6 cycloalkyl optionally substituted by one or more halogen atoms; hydroxy; C 1 -C 6 alkoxy optionally substituted by one or more halogen atoms; C 1 -C 6 alkyl-O—CH 2 —; C 1 -C 6 alkyl-O—CH(R X )— and C 1 -C 6 alkyl-O—C(R X R Y )— in which the C 1 -C 6 alkyl part is optionally substituted by one or more halogen atoms; NH 2 C(═O)—; R X NHC(═O)—; R X R Y NC(═O)—; R X R Y NS(═O) 2 —; R X NHS(═O) 2 —; NH 2 S(═O) 2 —; NH 2 —; R X NH—; R X R Y N—; R X S(═O) 2 —; R X C(═O)—; R X S(═O) 2 NH—; R X S(═O) 2 NR Y —; R X C(═O)NH— and R X C(═O)N(R Y )—; wherein R X R Y are independently C 1 -C 4 alkyl or C 3 -C 6 cycloalkyl, either of which being optionally substituted by one or more halogen atoms; or R X and R Y when attached to the same nitrogen atom form a cyclic amino ring; and

R 8 is hydrogen, C 1 -C 6 alkyl or C 3 -C 6 cycloalkyl, the latter two groups being optionally substituted by one or more halogen atoms.

2. The compound as claimed in claim 1 wherein R 1 is fluoro or chloro.

3. The compound as claimed in claim 1 wherein one of R 3 and R 4 is methyl, ethyl or isopropyl, and the other is methyl or difluoromethoxy.

4. The compound as claimed in claim 1 , wherein X is —CH 2 —.

5. The compound as claimed in claim 1 wherein R 1 is chloro or fluoro, R 2 is hydrogen or methyl, R 3 is methyl or difluoromethoxy, R 4 is ethyl, isopropyl or difluoromethoxy, R 5 is hydrogen, fluoro or chloro, one of Y and Y 1 is hydrogen and the other is pyrimidin-2-yl, pyrazol-1-yl, pyrazol-3-yl, pyrazol-4-yl, imidazol-1-yl, imidazol-2-yl, thiazol-2-yl, oxazol-2-yl or isoxazol-4-yl, any of which may be optionally substituted by one or more substituents selected from fluoro, chloro cyano methyl, ethyl, isopropyl, trifluoromethyl, difluoromethyl, cyclopropyl, hydroxy, methoxy, ethoxy, isopropoxy, difluoromethoxy, trifluoromethoxy, Z—O—CH 2 —, Z—O—CH(R X )— and Z—O—C(R X R Y )—, NH 2 C(═O)—; R X NHC(═O)—; R X R Y NC(═O)—; R X R Y NS(═O) 2 —; R X NHS(═O) 2 —; NH 2 S(═O) 2 —; NH 2 —; R X NH—; R X R Y N—; R X S(═O) 2 —; R X C(═O)—; R X S(═O) 2 NH—; R X S(═O) 2 NR Y —; R X C(═O)NH— and R X C(═O)N(R Y )—; wherein Z is selected from methyl, ethyl, isopropyl, trifluoromethyl, difluoromethyl, and cyclopropyl, and R X and R Y are independently methyl, ethyl, isopropyl, trifluoromethyl, difluoromethyl, or cyclopropyl, or R X and R Y when attached to the same nitrogen atom form a morpholino, piperidinyl, or piperazinyl ring, the latter being optionally N-substituted by methyl, ethyl, isopropyl or cyclopropyl.

6. The compound as claimed in claim 1 which is selected from the group consisting of:

[4-difluoromethoxy-2-ethyl-8-fluoro-3-(4-pyrazol-1-ylbenzyl) quinolin-5-yloxy]acetic acid;

[4-difluoromethoxy-2-ethyl-8-fluoro-3-(4-oxazol-2-ylbenzyl)quinolin-5-yloxy]acetic acid;

[4-difluoromethoxy-2-ethyl-8-fluoro-3-(4-methoxybenzyl)quinolin-5-yloxy]acetic acid;

[4-difluoromethoxy-3-(4-ethanesulfonylaminobenzyl)-2-ethyl-8-fluoroquinolin-5-yloxy]acetic acid;

[3-(4-acetylbenzyl)-4-difluoromethoxy-2-ethyl-8-fluoroquinolin-5-yloxy]acetic acid;

{4-difluoromethoxy-2-ethyl-8-fluoro-3-[4-(1-methyl-1H-imidazol-2-yl)benzyl]quinolin-5-yloxy}acetic acid;

[8-chloro-4-difluoromethoxy-2-ethyl-3-(4-pyrazol-1-ylbenzyl) quinolin-5-yloxy]acetic acid;

[4-difluoromethoxy-2-ethyl-8-fluoro-3-(4-thiazol-2-ylbenzyl)quinolin-5-yloxy]acetic acid;

[4-difluoromethoxy-2-ethyl-8-fluoro-3-(4-pyrimidin-2-ylbenzyl)quinolin-5-yloxy]acetic acid;

{8-chloro-4-difluoromethoxy-3-[4-(2,2-dimethylpropionyl)benzyl]-2-ethylquinolin-5-yloxy}acetic acid;

[8-chloro-2-methoxy-4-methyl-3-(4-pyrazol-1-ylbenzyl)quinolin-5-yloxy]acetic acid;

[2-difluoromethoxy-8-fluoro-4-methyl-3-(4-pyrazol-1-ylbenzyl)quinolin-5-yloxy]acetic acid;

[8-chloro-2-difluoromethoxy-4-methyl-3-(4-pyrazol-1-ylbenzyl)quinolin-5-yloxy]acetic acid;

[8-chloro-4-difluoromethoxy-2-ethyl-3-(4-isobutyrylbenzyl)quinolin-5-yloxy]acetic acid;

[8-fluoro-2-methoxy-4-methyl-3-(4-pyrazol-1-yl-benzyl)quinolin-5-yloxy]acetic acid;

[4-difluoromethoxy-2-ethyl-8-fluoro-3-(4-trifluoromethoxybenzyl)quinolin-5-yloxy]acetic acid;

{8-chloro-2-difluoromethoxy-3-[4-(2,2-dimethylpropionyl)benzyl]-4-methylquinolin-5-yloxy}acetic acid;

{3-[4-(4-chloropyrazol-1-yl)benzyl]-4-difluoromethoxy-2-ethyl-8-fluoroquinolin-5-yloxy}acetic acid;

[8-chloro-4-difluoromethoxy-2-isopropyl-3-(4-pyrazol-1-ylbenzyl)quinolin-5-yloxy]acetic acid;

{3-[4-(3-chloropyrazol-1-yl)benzyl]-4-difluoromethoxy-2-ethyl-8-fluoroquinolin-5-yloxy}acetic acid;

[4-difluoromethoxy-8-fluoro-2-isopropyl-3-(4-pyrazol-1-ylbenzyl)quinolin-5-yloxy]acetic acid;

{4-difluoromethoxy-2-ethyl-8-fluoro-3-[4-(1-isopropyl-1H-pyrazol-3-yl)benzyl]quinolin-5-yloxy}acetic acid;

{3-[4-(4-cyclopropylpyrazol-1-yl)benzyl]-4-difluoromethoxy-2-ethyl-8-fluoroquinolin-5-yloxy}acetic acid;

{4-difluoromethoxy-2-ethyl-8-fluoro-3-[4-(2-isopropylimidazol-1-yl)benzyl]quinolin-5-yloxy}acetic acid;

{3-[4-(3-cyclopropylpyrazol-1-yl)benzyl]-4-difluoromethoxy-2-ethyl-8-fluoroquinolin-5-yloxy}acetic acid;

{3-[4-(5-cyclopropylpyrazol-1-yl)benzyl]-4-difluoromethoxy-2-ethyl-8-fluoroquinolin-5-yloxy}acetic acid;

{3-[4-(5-cyclopropylisoxazol-4-yl)benzyl]-4-difluoromethoxy-2-ethyl-8-fluoroquinolin-5-yloxy}acetic acid;

{2-difluoromethoxy-3-[4-(2,2-dimethylpropionyl)benzyl]-8-fluoro-4-methylquinolin-5-yloxy}acetic acid;

{8-chloro-2-difluoromethoxy-4-methyl-3-[4-(1H-pyrazol-4-yl)benzyl]quinolin-5-yloxy}acetic acid;

{8-chloro-2-difluoromethoxy-3-[4-(1-isopropyl-1H-pyrazol-3-yl)benzyl]-4-methylquinolin-5-yloxy}acetic acid;

{8-chloro-2-difluoromethoxy-3-[4-(1-isopropyl-1H-pyrazol-4-yl)benzyl]-4-methylquinolin-5-yloxy}acetic acid;

{8-chloro-3-[4-(3-cyclopropylpyrazol-1-yl)benzyl]-2-difluoromethoxy-4-methylquinolin-5-yloxy}acetic acid and {8-chloro-3-[4-(5-cyclopropyl-pyrazol-1-yl)benzyl]-2-difluoromethoxy-4-methylquinolin-5-yloxy}acetic acid;

{3-[4-(5-cyclopropylpyrazol-1-yl)benzyl]-2-difluoromethoxy-8-fluoro-4-methylquinolin-5-yloxy}acetic acid;

{3-[4-(4-cyclopropylpyrazol-1-yl)benzyl]-2-difluoromethoxy-8-fluoro-4-methylquinolin-5-yloxy}acetic acid;

{2-difluoromethoxy-8-fluoro-3-[4-(2-isopropylimidazol-1-yl)benzyl]-4-methylquinolin-5-yloxy}acetic acid;

{8-chloro-3-[4-(4-cyclopropylpyrazol-1-yl)benzyl]-2-difluoromethoxy-4-methylquinolin-5-yloxy}acetic acid;

{3-[4-(3-cyclopropylpyrazol-1-yl)benzyl]-2-difluoromethoxy-8-fluoro-4-methylquinolin-5-yloxy}acetic acid;

{8-chloro-3-[4-(3-chloropyrazol-1-yl)benzyl]-2-difluoromethoxy-4-methylquinolin-5-yloxy}acetic acid;

{3-[4-(5-cyclopropylisoxazol-4-yl)benzyl]-2-difluoromethoxy-8-fluoro-4-methylquinolin-5-yloxy}acetic acid;

{8-chloro-3-[4-(4-chloropyrazol-1-yl)benzyl]-2-difluoromethoxy-4-methylquinolin-5-yloxy}acetic acid;

{8-chloro-2-difluoromethoxy-3-[4-(2-isopropylimidazol-1-yl)benzyl]-4-methylquinolin-5-yloxy}acetic acid;

[8-fluoro-2-isopropyl-4-methyl-3-(4-pyrazol-1-ylbenzyl)quinolin-5-yloxy]acetic acid;

[8-chloro-2-isopropyl-4-methyl-3-(4-pyrazol-1-ylbenzyl)quinolin-5-yloxy]acetic acid;

[8-chloro-2-isopropyl-4-methyl-3-(4-pyrazol-1-ylbenzyl)quinolin-5-yl]acetic acid;

(S)-2-[2-cyclopropyl-8-fluoro-4-methyl-3-(4-pyrazol-1-ylbenzyl)quinolin-5-yloxy]propionic acid, and pharmaceutically acceptable salts thereof.

7. A pharmaceutical composition comprising a compound as claimed in claim 1 , in admixture with a pharmaceutically acceptable carrier or excipient.

8. The compound as claimed in claim 1 , which is [2-cyclopropyl-8-fluoro-4-methyl-3-(4-pyrazol-1-ylbenzyl)quinolin-5-yloxy]acetic acid, or a pharmaceutically acceptable salt thereof.